½áÖ±³¦°©£¨colorectal cancer, CRC£©ÊÇ×î³£¼ûµÄÏû»¯µÀ¶ñÐÔÖ×ÁöÖ®Ò»£¬ÔçÆÚ·¢Ã÷½áÖ±³¦°©Óë¸ÄÉÆÉúÑÄЧ¹ûÇ×½üÏà¹Ø¡£ctDNA¼×»ù»¯×÷ΪһÖÖ±í¹ÛÒÅ´«ÐÞÊΣ¬ÒѾÒýÆðÔ½À´Ô½¶àµÄ¹Ø×¢¡£±¾Æª×ÛÊöMethylated circulating tumor DNA as a biomarker for colorectal cancer diagnosis, prognosis, and prediction£¬ÏêϸÐðÊöÁËct DNA¼×»ù»¯×÷ΪÉúÎï±ê¼ÇÎïÔÚ½áÖ±³¦°©Õï¶Ï¡¢Ô¤ºóºÍÕ¹ÍûÖеÄÓ¦Óá£
ÔÚ¶à¸öÑо¿Öз¢Ã÷µÄ½áÖ±³¦°©¼ì²âµÄÉúÎï±ê¼ÇÎï°üÀ¨BCAT1(Ö§Á´°±»ùËáתëÄø1)¡¢IKZF1(IKAROS¼Ò×åпָ1)¡¢SDC2(syndecan-2)¡¢ALX4(aristalless-ÑùͬԴºÐ4)¡¢SFRP2(ÉøÍ¸¾íÇúÏà¹ØÂѰ×2)¡¢OSMR(Ö×ÁöÒÖÖÆËØMÊÜÌå)¡¢SFRP1(ÉøÍ¸¾íÇúÏà¹ØÂѰ×1)ºÍVIM(vimentin)¡£BCAT1»ùÒò±àÂëÒ»ÖÖ¼ÓÈëÖ§Á´°±»ùËáÆÊÎö´úлµÄø£¬IKZF1»ùÒò±àÂëµ÷¿Ø²¿·Öϸ°ûÖÜÆÚµ÷¿Ø»ùÒòµÄת¼Òò×Ó¡£BCAT1ºÍIKZF1¶ÔCRC¼ì²âµÄÃô¸ÐÐÔ»®·ÖΪ47.3% ~ 64.9%ºÍ48% ~ 67.6%¡£±ðµÄ£¬Ëæ×ŽáÖ±³¦°©·ÖÆÚµÄÔöÌí£¬ÑôÐÔÂÊÒ²»áÔöÌí£¬µ«ÏÙÁöµÄÑôÐÔÂʺܵ͡£ÁíÒ»¸öÒѱ¨µÀµÄ»ùÒòSDC2ÔÚ½áÖ±³¦°©Ï¸°ûÖÐÔö½øÏ¸°ûÔöÖ³¡¢Ç¨áãºÍÇÖÏ®£¬ÒÖÖÆÏ¸°ûµòÍö£¬¼¤»îÉÏÆ¤-¼ä³äÖÊת»¯(EMT)ºÍË¿ÁÑԻÂѰ׼¤Ã¸(MAPK)ÐźÅͨ·¡£SDC2¿ÉÄÜÊÇÒ»ÖÖºÜÊÇÓÐǰ;µÄCRC¼ì²â¼×»ù»¯±ê¼ÇÎ¶ÔËùÓн׶εÄÃô¸ÐÐÔÔÚ69 - 87%Ö®¼ä£¬¶ÔCRC»¼ÕßѪ½¬/ѪÇåµÄÌØÒìÐÔԼΪ95%¡£
¶àÏîÑо¿ÅúעͬʱÆÊÎö¶à¸ö¸ß¼×»ù»¯Ñ»·DNAÔÚ¼ì²âCRC·½Ãæ±Èµ¥¸ö»ùÒò¸üÃô¸Ð¡£¶àÏîÑо¿Åú×¢£¬Ò»×麬ÓÐmSEPT9µÄ¼×»ù»¯»ùÒò¿ÉÄÜÔÚ°©Ç°²¡±äºÍÔçÆÚCRCµÄ¼ì²âÖÐÓÐÁÙ´²¼ÛÖµ¡£Í¬Ê±ÆÊÎöSEPT9ºÍSDC2ÔöÌíÁËËùÓÐ·ÖÆÚºÍÿ¸ö·ÖÆÚµÄÃô¸ÐÐÔ£¬µ«¶ÔÌØÒìÐÔûÓÐÏÔÖøÓ°Ïì¡£ÕâЩÑо¿Åú×¢¼×»ù»¯µÄSEPT9ºÍSDC2¿ÉÄÜÊÇÔçÆÚCRCɸ²éµÄ×î¼Ñ×éºÏÖ®Ò»¡£
»ùÓÚ±¾Æª×ÛÊö£¬ctDNA¼×»ù»¯×÷ΪCRCÕï¶Ï¡¢Ô¤ºóºÍÕ¹ÍûµÄÑ»·ÉúÎï±ê¼ÇÎï¾ßÓкܺõÄÔ¶¾°¡£´ó¹æÄ£µÄÁÙ´²ÊÔÑéºÍÑé֤˵Ã÷ctDNA¼×»ù»¯¿ÉÒÔ¸ÄÉÆCRCµÄÔçÆÚ·¢Ã÷ºÍ»¼ÕßµÄÕչ˻¤Ê¿ºÍ¼à²â¡£
²Î¿¼ÎÄÏ×
Clin Epigenetics. 2021 May 17;13(1):111.doi: 10.1186/s13148-021-01095-5.